ПРОМЕЖУТОЧНАЯ ПОЛИТИКА В ОТНОШЕНИИ СОТРУДНИЧЕСТВА В ОБЛАСТИ ТБ/ВИЧ [Interim Policy on Collaborative TB/HIV Activities]
This guideline promotes collaboration between TB and HIV/AIDS programs to reduce the burden for people affected by both diseases.
This guideline promotes collaboration between TB and HIV/AIDS programs to reduce the burden for people affected by both diseases.
This guideline promotes collaboration between TB and HIV/AIDS programs to reduce the burden for people affected by both diseases.
This fact sheet summarizes global goals and targets for TB control. The fact sheet also contains a data table with demographic, epidemiological, and operational indicators; threats to TB control; and resources for all the countries in the Americas.
This report discusses ways to reduce the spread and impact of infectious diseases, such as the six most deadly: HIV/AIDS, pneumonia, diarrhea, malaria, measles, and TB.
This report presents information about the Global TB Drug Facility, a program designed to ensure access to and the availability of TB drugs.
This report discusses the global efforts of national education and advocacy events that occurred on World Tuberculosis (TB) Day 2002. The report provides information about campaigns that promoted TB prevention through socioeconomic change, government support, the formation of partnerships between governments and nongovernmental organizations (NGOs), and improved healthcare access and delivery.
This report, updated annually, details the global epidemiology of TB based on the data supplied by the national TB programs from WHO member states.
These guidelines are designed to aid central units of national TB and HIV/AIDS programs work with districts to implement collaborative TB/HIV activities.
These guidelines have been developed to assist national TB control programs (NTPs) in adopting specific anti-TB drug resistance surveillance systems to measure susceptibility to first-line TB drugs.
This fact sheet explains the purpose of the Global Drug Facility (GDF) to expand access to, and availability of, high-quality TB drugs to facilitate DOTS expansion, and to enable governments and nongovernmental organizations (NGOs) to implement effective TB control programs based upon the DOTS stragegy.